BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 38268926)

  • 21. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies.
    Melaiu O; Vanni G; Portarena I; Pistolese CA; Anemona L; Pomella S; Bei R; Buonomo OC; Roselli M; Mauriello A; Barillari G
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer.
    Pingili AK; Chaib M; Sipe LM; Miller EJ; Teng B; Sharma R; Yarbro JR; Asemota S; Al Abdallah Q; Mims TS; Marion TN; Daria D; Sekhri R; Hamilton AM; Troester MA; Jo H; Choi HY; Hayes DN; Cook KL; Narayanan R; Pierre JF; Makowski L
    Cell Rep; 2021 Jun; 35(12):109285. PubMed ID: 34161764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
    Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
    Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
    Cao J; Yan Q
    Trends Cancer; 2020 Jul; 6(7):580-592. PubMed ID: 32610068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
    Qi J; Jin F; Xu X; Du Y
    Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
    Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CTLA-4 Expression and Its Clinical Significance in Breast Cancer.
    Kern R; Panis C
    Arch Immunol Ther Exp (Warsz); 2021 Jun; 69(1):16. PubMed ID: 34148159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies.
    Trnkova L; Buocikova V; Mego M; Cumova A; Burikova M; Bohac M; Miklikova S; Cihova M; Smolkova B
    Biomed Pharmacother; 2024 May; 174():116559. PubMed ID: 38603889
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
    Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Host response to immune checkpoint inhibitors contributes to tumor aggressiveness.
    Khononov I; Jacob E; Fremder E; Dahan N; Harel M; Raviv Z; Krastev B; Shaked Y
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy.
    Cruickshank B; Giacomantonio M; Marcato P; McFarland S; Pol J; Gujar S
    Front Immunol; 2018; 9():654. PubMed ID: 29666625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Wu J; Wang W; Gao L; Shao X; Wang X
    Cancer; 2024 Apr; 130(S8):1449-1463. PubMed ID: 38482921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. H3K4 trimethylation regulates cancer immunity: a promising therapeutic target in combination with immunotherapy.
    Xiao C; Fan T; Zheng Y; Tian H; Deng Z; Liu J; Li C; He J
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
    Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy.
    Zhou L; Zhang P; Wang H; Wang D; Li Y
    Acc Chem Res; 2020 Sep; 53(9):1761-1772. PubMed ID: 32819102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.